# Complement Regulation to Undo Systemic Harm in Preeclampsia

> **NCT04725812** · PHASE2 · TERMINATED · sponsor: **Cedars-Sinai Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Preeclampsia
- Severe Preeclampsia
- Eculizumab
- HELLP
- HELLP Syndrome
- HELLP Syndrome Second Trimester
- Pregnancy Related
- AHUS
- PNH
- Complement Regulatory Factor Defect
- Complement Abnormality
- HELLP Syndrome Third Trimester

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT04725812
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-13
- **Primary completion:** 2021-12-07
- **Final completion:** 2021-12-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** PI moved institutions
- **Last updated:** 2023-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04725812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04725812, "Complement Regulation to Undo Systemic Harm in Preeclampsia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04725812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*